Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

A poster from YMB looked into “CYDY license rela

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153798
(Total Views: 1491)
Posted On: 08/21/2020 12:46:15 AM
Posted By: tsn
A poster from YMB looked into “CYDY license related questions and how previous license agreements can affect CYDY's EPS and for that matter benefit other companies. I am enclosing a document which I previously shared. I am not certain whether AbbVie (think of blockbuster Humira) gets 3.5% or 4.5% on net sales. The master license agreement states 4.5% while CYDY's filings states 3.5%.

CytoDyn faces the possibility of generating Billions in revenues if all the planets align perfectly. Regardless of the exact amount, Lantheus Holdings (after the merge with Progenics) will receive 5% of PRO140 (Leronlimab) net sales. AbbVie will receive an additional 3.5%-4.5%. Thus, any calculation about future share values for the next 10 years should take these royalty payments into consideration. Clearly, the BIG winner is LNTH. Specifically, LNTH will receive another $50 million for each $1.0 Billion of net sales. LNTH revenues are small viv a vis AbbVie. This initial $55 million represents for LNTH a diluted EPS increase of 55-66 cents based on the royalty payments ESP assumptions found on page 20 of LNTH's 11/19/19 pre-merger presentation. A future LNTH share +4X price increase to at least $62 is easily attainable and probably significantly higher. My calculations are based on LNTH's own management royalty payments ESP assumptions which I found on page 20 of the following 11/19 presentation. https://lantheusprogenics.transactionannounce...7.19_..pdf .
It is a fascinating story behind how AbbVie eventually became the Master licensor of PRO140. It goes more or less as follows. PRO140 ( Leronlemab’ IP foundation) was developed and licensed by Protein Design Labs for Progenics in1999 (Progenics later sublicensed it to CytoDyn in 2012). The license calls for a 5% royalty fee (plus certain payments) on the Net Sales of all Licensed Products sold by Progenics or its Affiliates or sublicensees.
www.sec.gov/Archives/edgar/data/1175680/000119312513351909/d541269dex1021.htm

Protein Design Labs eventually became Bio Pharma (PDL) and in 2008 it created and funded an independent company called Facet Biotech which kept the PRO140 license. Facet Biotech’s 2009 10K described its license relationship with Progenics as follows:“”Progenics Pharmaceuticals Inc.—In 1999, we entered into a humanization agreement with Progenics whereby we humanized an antibody targeted to the CCR5 receptor (designated by Progenics as PRO 140)”.
To avoid a hostile takeover, Facet Biotech in 2010 sought out a White Knight. Thus, Abbott Laboratories acquired the company for $27 per share. Late 2011, Abbott announced plans to split into two companies—one in diversified medical products (Abbott) and a new one (AbbVie) in research-based pharmaceuticals. The license for PRO140 stayed with AbbVie giving the company a priviliged permanent insight into CytoDyn's future market success.
Since 2012, AbbVie has nearly doubled revenues, growing from $18.8 billion following the spin-off to $33.3 billion in 2019 with Humira representing over 50% of revenues. AbbVie needs diversification with license deals such as the one you mentioned and the recent Allergan mega deal. At the time I did my due diligence concerning CYDY's PRO140 sub license, AbbVie had a $40 billion cash kitty. CytoDyn could be a potential acquisition or license candidate because the PRO140 IP could be used in a number of profitable therapeutic spaces which overlap with AbbVie's strategic priorities.
As Progenics was developing this molecule for years before Cytodyn licensed it and Cytodyn has been slow in their development, the initial (not all) patents are going to be gone not to far in the future. The key dates to consider: a.) Progenics/Abbvie licenses are 10 years from BLA approval date and b.) FDA's BLA license that gives Cytodyn exclusivity for 12 years from the date of approval. Those are the key calendar items for licenses. Patents are less of an issue in biologics.”


(3)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us